
AstraZeneca signs respiratory deal
pharmafile | January 29, 2013 | News story | Research and Development, Sales and Marketing | AstraZeneca, COPD, orexo, respiratory
AstraZeneca has signed a research deal with Swedish pharma company Orexo centred around the development of respiratory disease treatments.
For an undisclosed sum, Orexo is giving AstraZeneca rights to conduct further pre-clinical research and evaluation of compounds in Orexo’s OX-CLI programme.
It is aimed at finding a novel treatment for various conditions, and AstraZeneca has an option to acquire the compounds “subject to a full asset transfer agreement being executed by the parties”.
If it comes off, Orexo would receive development milestone payments and royalties on future sales.
“Our OX-CLI program is a promising R&D project, which has potential to improve the treatment of respiratory diseases for millions of patients,” said chief executive Anders Lundström.
AstraZeneca’s Symbicort is already one of the biggest-selling drugs in the chronic obstructive pulmonary disease (COPD) market.
The new deal is the latest in a line of partnerships for Orexo, which has R&D or marketing and sales agreements with companies including Boehringer Ingelheim and Novartis.
Orexo’s Abstral, which provides rapid onset of relief of breakthrough pain in cancer, was launched by ProStrakan Group in Europe in 2008 and in US in 2011.
Adam Hill
Related Content

NICE recommends Benralizumab for Rare Form of Vasculitis
The National Institute for Health and Care Excellence (NICE) has recommended AstraZeneca’s benralizumab (Fasenra) as …

NICE approves AstraZeneca’s dual immunotherapy for advanced liver cancer
AstraZeneca has received a positive recommendation from the National Institute for Health and Care Excellence …

Purpose and people: the enduring power of brand and the evolution of employer identity
Two decades ago, terms like purpose and people were rarely at the forefront of branding …






